Emerging Trends to Reshape the Myelodysplastic Syndrome Market: Bristol Myers Squibb Gains FDA Approval for Reblozyl as First-Line Therapy for Anemia in Myelodysplastic Syndrome Patients as a Key Influencer

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

Myelodysplastic Syndrome Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent years, the market size for myelodysplastic syndrome has experienced considerable growth. Predictions indicate it will increase from $2.56 billion in 2024 to $2.85 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.3%. The historic period of growth is due to a rise in the incidence of myelodysplastic syndrome, increased knowledge concerning treatment options, elevated healthcare expenditure, and governmental efforts.

Myelodysplastic Syndrome Market Size Forecast: What's the Projected Valuation by 2029?
There is an anticipation of significant expansion in the myelodysplastic syndrome market in the upcoming years, with the market size predicted to reach $4.17 billion by 2029, showing a compound annual growth rate (CAGR) of 10.0%. The notable growth in the forecasted period could be linked to several factors such as the increasing aging population, the use of combination therapies, financial investment in hematologic studies, and personalized medicine. In the prediction timeframe, there are major trends to look out for, including the development of new treatments for myelodysplastic syndrome, progress in diagnostic tools and methods, clinical trials, and cooperative research.

View the full report here:
https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-global-market-report

What Are the Drivers Transforming the Myelodysplastic Syndrome Market?
The rise in rare blood cancer cases is projected to spur the expansion of the myelodysplastic syndrome (MDS) market. Blood malignancies, characterized by a low prevalence rate in the population, typically stem from the cells of the bone marrow, lymph nodes and other components of the blood and immune system. MDS treatment primarily focuses on blood cell production improvement and alleviating related symptoms to hinder the advancement of bone marrow blood cancer. For instance, the Leukemia and Lymphoma Society noted in September 2024 that someone in the US is diagnosed with leukemia, lymphoma, or myeloma every three minutes. In 2024, it is predicted that 187,740 individuals will grapple with these cancers, making up 9.4% of the projected 2,001,140 new cancer cases in the US. As such, the escalating cases of blood cancer fuel the expansion of the MDS market. The widening scope of the Myelodysplastic Syndrome market is prompted by the projected increase in bone marrow transplants, serving as a significant driver for the market's growth. Bone marrow transplants, being medical procedures that replace unhealthy stem cells with healthy ones in damaged or diseased bone marrows, are known to treat various conditions. MDS, often characterized by malfunctioning bone marrow, ensues due to the selective growth of somatically changed clonal hematopoietic stem cells. Replacing these abnormal stem cells through bone marrow transplantation can potentially treat MDS. The National Transplant Organization (ONT) in Spain reported in June 2024 that the Spanish Bone Marrow Donor Registry added 23,686 donors in 2023, an 8% increase from the previous year. Additionally, a record-high 3,717 hematopoietic stem cell transplants were performed, equating to 77.4 transplants per million people. Thus, the steady rise in the number of bone marrow transplants is spearheading the growth of the MDS market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12920&type=smp

What Long-Term Trends Will Define the Future of the Myelodysplastic Syndrome Market?
In a bid to solidify their position in the myelodysplastic syndrome (MDS) market, leading firms are creating innovative therapies. For example, Bristol Myers Squibb, a pharmaceutical company based in the US, received FDA approval for Reblozyl (luspatercept-aamt) as the initial treatment for anemia in ESA-naïve adults with low to intermediate-risk MDS who may require frequent RBC transfusions in August 2023. Reblozyl demonstrated superior potency in the Phase 3 COMMANDS trial by achieving RBC transfusion independence and increasing hemoglobin levels over epoetin alfa. This is set to tackle anemia in a wider patient pool at an earlier stage.

Which Segments in the Myelodysplastic Syndrome Market Offer the Most Profit Potential?
The myelodysplastic syndrome market covered in this report is segmented -

1) By Type: Myelodysplastic Syndrome With Unilineage Dysplasia, Myelodysplastic Syndrome With Multilineage Dysplasia, Myelodysplastic Syndrome With Ring Sideroblasts, Other Types
2) By Drug: Azacitidine, Lenalidomide, Decitabine, Deferasirox
3) By Treatment: Supportive Therapy, Growth Factors, Chemotherapy, Stem Cell Transplant, Other Treatments
4) By Route Of Administration: Oral, Injectable, Other Routes Of Administrations
5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:
1) By Myelodysplastic Syndrome With Unilineage Dysplasia: Type Of Dysplasia, Patient Demographics
2) By Myelodysplastic Syndrome With Multilineage Dysplasia: Severity Of Dysplasia, Patient Demographics
3) By Myelodysplastic Syndrome With Ring Sideroblasts: Percentage Of Ring Sideroblasts, Treatment Options
4) By Other Types: Specific Types, Treatment Options

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12920&type=smp

Which Firms Dominate the Myelodysplastic Syndrome Market by Market Share and Revenue in 2025?
Major companies operating in the myelodysplastic syndrome market are Pfizer Inc., Johnson and Johnson Limited, AbbVie Inc., Bayer AG, Novartis AG, Merck & Co., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., Takeda Pharmaceutical Company Limited, Medtronic PLC, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Jazz Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Lupin Limited, BeiGene, Janssen Biotech, Accord Healthcare, Acceleron Pharma Inc.

Which Regions Offer the Highest Growth Potential in the Myelodysplastic Syndrome Market?
North America was the largest region in the myelodysplastic syndrome market in 2024. The regions covered in myelodysplastic syndrome (MDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12920

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.